First Round of abstract submission : January 28 , 2018 | Welcome Message

Theme : Novel Research and Diagnostic Mechanism for Improving Alzheimer’s and Parkinson’s Disease

Organizing Committee Members

ABOUT CONFERENCE

Science Access invites all the participants from all over the world to attend World Conference on Alzheimer's and Parkinson Diseases which will be held during April 16-18, 2018 in Tokyo, Japan. The conference mainly focuses “Novel Research and Diagnostic Mechanism for Improving Alzheimer’s and Parkinson’s Disease”.
Dementia is a loss of mental ability severe enough to interfere with normal activities of daily living, lasting more than six months, not present since birth, and not associated with a loss or alteration of consciousness.
Dementia is a group of symptoms caused by the gradual death of brain cells. The loss of cognitive abilities that occurs with dementia leads to impairments in memory, reasoning, planning, and behavior. While the overwhelming number of people with dementia are elderly, dementia is not an inevitable part of aging; instead, dementia is caused by specific brain diseases. Alzheimer's disease (AD) is the most common cause, followed by vascular or multi-infarct dementia.
 
The prevalence of dementia is difficult to determine, partly because of differences in definition among different studies and partly because there is some normal decline in functional ability with age. The prevalence of dementia roughly doubles for every five years of age beginning at age 60. Dementia affects about 1% of people between ages 60 and 64, 5-8% of all people between ages 65 and 74, up to 20% of those between 75 and 84, and between 30% and 50% of those age 85 and older. About 60% of nursing home patients have dementia. The Alzheimer's Association estimates that in 2007, 5.1 million Americans were living with a diagnosis of an AD. That number expected to grow substantially as the population ages.
The cost of dementia can be considerable. While most people with dementia are retired and are not affected by income losses from their disease, the cost of care often is enormous. Financial burdens include lost wages for family caregivers, medical supplies and drugs, and home modifications to ensure safety. Nursing home care may cost several thousand dollars a month or more. The psychological cost is not as easily quantifiable but can be even more profound. The person with dementia loses control of many of the essential features of his life and personality, and loved ones lose a family member even as they continue to cope with the burdens of increasing dependence and unpredictability
Conference Highlights
·         200+ Participation (50% Academic: 30% Hospitals: 20% Industry)
·         9+ Keynote Speakers
·         30+ Plenary Speakers
·         3+ Exhibitors
·         14 Innovative Educational Sessions
·         B2B Meetings
·         Exhibition
 
Target Audience
·         Neurologists and Directors
·         Physicians
·         Neuroscientists
·         Specialists
·         researchers
·         Healthcare professionals
·         Professors
·         Industrial Experts
·         Neurosurgeons
·         Psychiatrist
·         Nutritional Scientists
·         Lecturers and Students from Academia in the study of Dementia
·         Students from Academia in the research of Neurology
 
Why should you attend?
Alzheimer’s Congress 2018 will give a chance to all partners chipping away at Alzheimer's infection and Dementia to discuss their work. Dementia 2018 will assemble prestigious speakers, important examiners, specialists, neurologist's and Dementia analysts from both scholarly community and social insurance industry will consolidate to talk about their perspectives and research. The gathering will be involved sessions by world-class specialists in the field of neurology. In Dementia 2018, global symposiums, B2B gatherings, worldwide workshops will likewise be sorted out to talk about the particular points in the field of Dementia and Neurology.
 
Market Analysis
Science Access Ltd arranges gathering arrangement all around the Globe in 2018. Here we invite you to the tenth World Congress on World Conference on Alzheimer's and Parkinson Diseases during April 16-18, 2018 in Tokyo, Japan.
 Alzheimer’s Congress predominantly concentrating on Alzheimer's illness, Dementia, Neurological changes in mind, Alzheimer's sickness Imaging, Disease Mechanisms, Geriatrics and Cognitive Disorder, Pathophysiology, Brain injury, Care practice and Awareness, Current Research in Alzheimer's and Parkinson's Diseases.
Importance and Scope: -
Dementia is a general term that portrays a gathering of side effects, for example, loss of memory, judgment, dialect, complex engine abilities, and other scholarly capacity caused by the lasting harm or passing of the cerebrum's nerve cells, or neurons.
Dementia, including Alzheimer's infection, is one of the greatest worldwide general wellbeing challenges confronting our era.
Universally, aftereffects of a current meta-investigation recommend that 44 million individuals lived with dementia worldwide in 2010, with numbers anticipated that would twofold at regular intervals, to 65.7 million of every 2030 and 115.4 million out of 2050. In 2010, 58 percent surprisingly with dementia lived in nations with low or center wages, with this extent foreseen to ascend to 63 percent in 2030 and 71 percent in 2050.This number is relied upon to twofold by 2030 and more than triple by 2050 to 115 million.
In the United States alone, specialists gauge that upwards of five million individuals age 65 and more established experience the ill effects of Alzheimer's sickness The AD market has a lack of therapeutic options. Which classes of drug dominate the market?
·        What newly approved therapies have entered the market?
·        How do the leading marketed therapies compare clinically?
·        How will the new therapies be positioned in the treatment of AD?
·        How have selected late-stage pipeline therapies performed in clinical trials?
·       The pipeline contains a range of molecule types and molecular targets, including those that are well                           
          established in the AD, and novel, first-in-class therapies.
·        Which molecular targets appear most frequently in the pipeline?
·        AD clinical trials have an overall attrition rate of 94%.
·        What are the failure rates for individual Phases of clinical development?
·       How do AD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?
·       The AD market is forecast to rise from a value of $5.2 billion in 2014 to $11.3 billion in 2021, at a CAGR of             11.8% across the eight major markets assessed.
·       How much of a role will disease prevalence and new product approvals play in market growth?
·        Will generic competition have a significant impact on the market over the forecast period?
·        There have been 170 licensing deals and 104 co-development deals pertaining to AD products since  2006.
·        Which territories show the most deal activity?
·        What were the trends in deal completion by-product stage of development?
·        What were the conditions of the key licensing or co-development deals to take place in the AD?
 
Why in Tokyo:
Tokyo is the biggest Metropolitan city in Japan. Glorify in a large number of individuals encountering mental issues excuse the perseverance of 47 affiliations and social orders subsidiary to Neuroscience in Tokyo and Japan. Japan is dislodging towards contemporary brain research industry from its conventional "shinigami".
Tokyo otherwise called the "metropolitan prefecture", Tokyo is a major international finance center, houses the headquarters of several of the world's largest investment banks and insurance companies, and serves as a hub for Japan's transportation, publishing, electronics and broadcasting industries. Tokyo is a noteworthy financial center point, facilitating almost 37.8 million individuals. Tokyo has the largest metropolitan economy in the world. The Tokyo urban area 38 million people had a total GDP of $2 trillion in 2012, which topped that list. 51 of the companies listed on the Fortune Global 500 are based in Tokyo, almost twice that of the second-placed city
Tokyo has many museums. In Ueno Park, there is the Tokyo National Museum, the country's largest museum and specializing in traditional Japanese art; the National Museum of Western Art and Ueno Zoo. Other museums include the National Museum of Emerging Science and Innovation in Odaiba; the Edo-Tokyo Museum in Sumida, across the Sumida River from the center of Tokyo; the Nezu Museum in Aoyama; and the National Diet Library, National Archives, and the National Museum of Modern Art.
Why attend???
World Conference on Alzheimer's and Parkinson Diseases is a one of a kind gathering to unite overall recognized scholastics in the field of neuroscience and neurology, Brain specialists, general wellbeing experts, researchers, scholastic researchers, industry analysts, researchers to trade about best in class research and advances
Point of this gathering is fortifying new thoughts for treatment that will be painful over the range of Neuroscience
A Unique Opportunity for Advertisers and Sponsors at this International occasion
For more points of interest please visit-  http://dementia.congressseries.com
UNIVERSITIES IN TOKYO & JAPAN
·        University of Tokyo
·        Waseda University
·        Keio University
·        Meiji University
·        Toyo University
·        Nihon University
·        Rikkyo University
·        Tokyo Medical and Dental University
·        Tokyo Women's Medical University
·        Chuo University
·        Tokyo City University
HOSPITALS IN TOKYO JAPAN
·        Jikei University School of Medicine Hospital
·        Jutendo Hospital
·        Keio University Hospital
·        King Clinic, The(Sanno Hospital)
·        National Cancer Center
·        National Hospital Organization Tokyo Medical Center
·        Tokyo Medical University Hospital
·        University of Tokyo Hospital
·        Self-Defense Forces Central Hospital
·        St. Luke's International Hospital
·        NTT Medical Center Tokyo
·        International Catholic Hospital (Seibo Hospital)
 Alzheimer’s association members
·         Rr. Themistokli Germenji (Albanian Alzheimer's Society)
·         Prof Michail Aghajanov Ph.D. (Yerevan State Medical University)
·         W. Suite(Alzheimer Society of Canada)
Companies Associated with Neurology in Japan are
Following are some companies in Japan which produce Neurology drugs they are:
·        Pfizer
·        GlaxoSmithKline
·        Solvay of Belgium
·        Fujisawa Pharmaceutical
·        Meiji Seika
·        Janssen Pharmaceutical
·        Lund beck
·        Asahi Kasei Corporation
·        Forest Laboratories
·        Eli Lilly
·        Wyeth Pharmaceuticals
·        Organon International
Major Associations around the Globe
·        Neuropathy Association
·        The brain & behavior research foundation
·        Alzheimer's Association
·        American Academy of Neurology
·        European Neurological Societies
·        World Federation of Neurology
·        Spanish Society of Neurology
·        Major Neurological Associations in Italy
·        Hilarescere Foundation in Italy
·        Italian MS society in Italy 
·        Southern Clinical Neurological Society
·        ESNR European Society of Neuroradiology
·        Vision sciences society
 
Around 500 top universities globally working in the field of Neuroscience
·        Dalhousie University
·        Leiden University- Neither land
·        Temple University the USA
·        University Oklahoma
·        Boston Coll the USA
·        Florida International University
·        University California – Davis
·        University Sheffield
·        University Manchester
·        University of Nottingham
·        Cardiff University
·        University of Toronto – Canada
·        Hospitals Associated with Neuroscience Research
All around the globe there are 6000 hospitals working on Neurology
·        Johns Hopkins Hospital
·        World Brain Center Hospital
·        Duke University Hospital
·        Edward Hospital
·        Munson Medical Center
 

big-event
big-event

Target Audience

  • Neurologists and Directors
  • Physicians
  • Neuroscientists
  • Psychiatrists
  • Psychologists
  • Neurosurgeons
  • Nutritional Scientists
  • Industrial Experts
  • Lecturers and Students from Academia in the study of Diseases
  • geriatricians

Contact Us

Feel Free To Contact Us

Address   : 2737 Live Oak Street, Huntington Park, CA 90255, USA
Phone No : +1-302-428-9993
Fax           : +1-302-428-9993
Email Id    : dementia@sasummits.com


MAIL US AT

Subscribe Neurology Conference
 

Authorization Policy: By registering for the conference you grant permission to SCIENCEACCESS to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or video recording by participants/others during conference is prohibited without prior approval. Contact us for any queries. Privacy is Everyone's Concern!